Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove Non-Inferiority of Fosfomycin vs Meropenem or Ceftriaxone in the Treatment of Bacteriemic Urinary Infection Due to Multidrug Resistance in E.Coli

NCT02142751 is registered in ClinicalTrials.gov with Fundación Pública Andaluza para la gestión de la Investigación en Sevilla as lead sponsor.

NCT NCT02142751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02142751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove Non-Inferiority of Fosfomycin vs Meropenem or Ceftriaxone in the Treatment of Bacteriemic Urinary Infection Due to Multidrug Resistance in E.Coli
Lead sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2014
Completion date
March 31, 2019
Enrollment
161 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

infection due to esbl escherichia coli